Researcher
Lars Devisscher
- Keywords:Pharmacy and pharmacology
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal chemistry, Medicinal products, Pharmaceutical analysis and quality assurance, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences, Other medical and health sciences
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2014 → 30 Sep 2018
Projects
1 - 2 of 2
- Discovery of necroptosis and ferroptosis inhibitors with potential applications in pathologies associated with regulated necrosis.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- Discovery of necroptosis and ferroptosis inhibitors with potential applications in pathologies associated with regulated necrosis.From1 Oct 2014 → 30 Sep 2016Funding: FWO fellowships
Publications
1 - 6 of 6
- Tozasertib analogues as inhibitors of necroptotic cell death(2018)
Authors: Sam Hofmans, Lars Devisscher, Sofie Martens, Dries Van Rompaey, Kenneth Goossens, Tatyana Divert, Wim Nerinckx, Nozomi Takahashi, Hans De Winter, Pieter Van Der Veken, et al.
Pages: 1895 - 1920 - Discovery of necroptosis and ferroptosis inhibitors with potential applications in pathologies associated with regulated necrosis(2018)
Authors: Lars Devisscher, Koen Augustyns, Hans De Winter
Number of pages: 428 - Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy(2018)
Authors: Lars Devisscher, Samaya Van Coillie, Sam Hofmans, Dries Van Rompaey, Kenneth Goossens, Eline Meul, Hans De Winter, Pieter Van Der Veken, Peter Vandenabeele, Tom Vanden Berghe, et al.
Pages: 10126 - 10140 - Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis(2018)
Authors: Isabelle Coornaert, Sam Hofmans, Lars Devisscher, Koen Augustyns, Pieter Van Der Veken, Guido De Meyer, Wim Martinet
Pages: 477 - 488 - RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680)(2018)
Authors: Sofie Martens, Vera Goossens, Lars Devisscher, Sam Hofmans, Polien Claeys, Marnik Vuylsteke, Nozomi Takahashi, Koen Augustyns, Peter Vandenabeele
- Novel ferroptosis inhibitors with improved potency and ADME properties(2016)
Authors: Sam Hofmans, Tom Vanden Berghe, Lars Devisscher, Behrouz Hassannia, Sophie Lyssens, Jurgen Joossens, Pieter Van Der Veken, Peter Vandenabeele, Koen Augustyns
Pages: 2041 - 2053
Patents
1 - 3 of 3
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)